Show simple item record

dc.contributor.authorFellenor, J
dc.contributor.authorBritten, N
dc.contributor.authorCourtenay, M
dc.contributor.authorPayne, RA
dc.contributor.authorValderas, J
dc.contributor.authorDenholm, R
dc.contributor.authorDuncan, P
dc.contributor.authorMcCahon, D
dc.contributor.authorTatnell, L
dc.contributor.authorFitzgerald, R
dc.contributor.authorWarmoth, K
dc.contributor.authorGillespie, D
dc.contributor.authorTurner, K
dc.contributor.authorWatson, M
dc.date.accessioned2021-01-22T16:13:52Z
dc.date.issued2021-01-13
dc.description.abstractBackground Up to 50% of medicines are not used as intended, resulting in poor health and economic outcomes. Medicines optimisation is ‘a person-centred approach to safe and effective medicines use, to ensure people obtain the best possible outcomes from their medicines’. The purpose of this exercise was to co-produce a prioritised research agenda for medicines optimisation using a multi-stakeholder (patient, researcher, public and health professionals) approach. Methods A three-stage, multiple method process was used including: generation of preliminary research questions (Stage 1) using a modified Nominal Group Technique; electronic consultation and ranking with a wider multi-stakeholder group (Stage 2); a face-to-face, one-day consensus meeting involving representatives from all stakeholder groups (Stage 3). Results In total, 92 research questions were identified during Stages 1 and 2 and ranked in order of priority during stage 3. Questions were categorised into four areas: ‘Patient Concerns’ [e.g. is there a shared decision (with patients) about using each medicine?], ‘Polypharmacy’ [e.g. how to design health services to cope with the challenge of multiple medicines use?], ‘Non-Medical Prescribing’ [e.g. how can the contribution of non-medical prescribers be optimised in primary care?], and ‘Deprescribing’ [e.g. what support is needed by prescribers to deprescribe?]. A significant number of the 92 questions were generated by Patient and Public Involvement representatives, which demonstrates the importance of including this stakeholder group when identifying research priorities. Conclusions A wide range of research questions was generated reflecting concerns which affect patients, practitioners, the health service, as well the ethical and philosophical aspects of the prescribing and deprescribing of medicines. These questions should be used to set future research agendas and funding commissions.en_GB
dc.description.sponsorshipGW4en_GB
dc.description.sponsorshipNational Institute for Health Research (NIHR)en_GB
dc.identifier.citationVol. 21, article 64en_GB
dc.identifier.doi10.1186/s12913-021-06056-5
dc.identifier.grantnumberGW4-IF10–001en_GB
dc.identifier.urihttp://hdl.handle.net/10871/124473
dc.language.isoenen_GB
dc.publisherBMCen_GB
dc.rights© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.en_GB
dc.subjectMedicines optimisationen_GB
dc.subjectPolypharmacyen_GB
dc.subjectDeprescribingen_GB
dc.subjectPatient concernsen_GB
dc.subjectNon-medical prescribingen_GB
dc.subjectNominal group techniqueen_GB
dc.titleA multi-stakeholder approach to the co-production of the research agenda for medicines optimisationen_GB
dc.typeArticleen_GB
dc.date.available2021-01-22T16:13:52Z
exeter.article-number64en_GB
dc.descriptionThis is the final version. Available on open access from BMC via the DOI in this recorden_GB
dc.descriptionAvailability of data and materials: The datasets used and/or analysed during the current exercise are available from the corresponding author on request.en_GB
dc.identifier.eissn1472-6963
dc.identifier.journalBMC Health Services Researchen_GB
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_GB
dcterms.dateAccepted2021-01-02
rioxxterms.versionVoRen_GB
rioxxterms.licenseref.startdate2021-01-13
rioxxterms.typeJournal Article/Reviewen_GB
refterms.dateFCD2021-01-22T16:11:16Z
refterms.versionFCDVoR
refterms.dateFOA2021-01-22T16:14:01Z
refterms.panelAen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record

© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
Except where otherwise noted, this item's licence is described as © The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.